These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 17680019)
21. Advances in therapy of multiple myeloma. Bladé J; Rosiñol L Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053 [TBL] [Abstract][Full Text] [Related]
22. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872 [TBL] [Abstract][Full Text] [Related]
23. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654 [TBL] [Abstract][Full Text] [Related]
24. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
25. The evolving background for high-dose treatment for myeloma. Sirohi B; Powles R; Harousseau JL; Anderson KC Bone Marrow Transplant; 2007 Dec; 40(12):1097-100. PubMed ID: 17906702 [TBL] [Abstract][Full Text] [Related]
26. The role of high-dose therapy with autologous stem cell support in the era of novel agents. Attal M; Harousseau JL Semin Hematol; 2009 Apr; 46(2):127-32. PubMed ID: 19389496 [TBL] [Abstract][Full Text] [Related]
27. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation? Willemze R; Labar B Semin Hematol; 2007 Oct; 44(4):267-73. PubMed ID: 17961726 [TBL] [Abstract][Full Text] [Related]
28. Initial therapy in multiple myeloma: investigating the new treatment paradigm. Kettle JK; Finkbiner KL; Klenke SE; Baker RD; Henry DW; Williams CB J Oncol Pharm Pract; 2009 Sep; 15(3):131-41. PubMed ID: 19276138 [TBL] [Abstract][Full Text] [Related]
29. Autologous stem cell transplantation beyond 60 years of age. Jantunen E Bone Marrow Transplant; 2006 Dec; 38(11):715-20. PubMed ID: 17041609 [TBL] [Abstract][Full Text] [Related]
37. Conventional therapy and approach to management. Rajkumar SV; Kyle RA Best Pract Res Clin Haematol; 2005; 18(4):585-601. PubMed ID: 16026739 [TBL] [Abstract][Full Text] [Related]
38. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204 [TBL] [Abstract][Full Text] [Related]
39. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968 [TBL] [Abstract][Full Text] [Related]
40. Modern treatment options for elderly patients with multiple myeloma. Görner M; Späth-Schwalbe E; Onkologie; 2008 Jun; 31(6):335-42. PubMed ID: 18547977 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]